ストックスクリーナーアプリを入手
6.81
4.77%
0.31
前日終値:
$6.50
開ける：
$6.63
24時間の取引高:
420.36K
Relative Volume:
1.38
時価総額：
$175.71M
収益：
$34.26M
当期純損益:
$-46.61M
株価収益率:
-1.3145
EPS:
-5.1806
ネットキャッシュフロー:
$-62.01M
1週間 パフォーマンス:
+10.37%
1か月 パフォーマンス:
-2.16%
6か月 パフォーマンス:
+50.66%
1年 パフォーマンス:
+44.89%
1日の値動き範囲:
$6.515
$6.98
1週間の範囲:
$6.055
$6.98
52週間の値動き範囲:
$3.53
$8.82
Precision Biosciences Inc Stock (DTIL) Company Profile
名前
Precision Biosciences Inc
セクター
電話
919-314-5512
住所
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
6.81 | 175.71M | 34.26M | -46.61M | -62.01M | -5.1806 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-10 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | 開始されました | Guggenheim | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-06-09 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | 再開されました | BTIG Research | Buy |
| 2020-04-03 | ダウングレード | Goldman | Buy → Neutral |
| 2020-03-05 | 開始されました | Stifel | Buy |
| 2020-02-25 | 開始されました | William Blair | Outperform |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-07-16 | 開始されました | H.C. Wainwright | Buy |
| 2019-04-22 | 開始されました | Barclays | Overweight |
| 2019-04-22 | 開始されました | Goldman | Buy |
| 2019-04-22 | 開始されました | JP Morgan | Overweight |
| 2019-04-22 | 開始されました | Jefferies | Buy |
すべてを表示
Precision Biosciences Inc (DTIL) 最新ニュース
Precision BioSciences Inc (DTIL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Precision BioSciences Inc (DTIL) Institutional Confidence - TradingKey
Precision BioSciences Inc (DTIL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Precision BioSciences Inc (DTIL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Precision BioSciences Inc (DTIL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Precision BioSciences Inc (DTIL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Precision BioSciences Extends Term Loan Maturity to 2029 in Amendment With Banc of California - TradingView
Precision BiosciencesEnters First Amendment To Loan And Security Agreement With Banc Of CaliforniaSEC Filing - TradingView
Precision BioSciences (NASDAQ: DTIL) amends loan and extends term to 2029 - Stock Titan
Precision BioSciences, Inc. Amends Loan and Security Agreement with Banc of California - marketscreener.com
Precision BioSciences Inc (DTIL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oppenheimer Maintains Precision BioSciences(DTIL.US) With Buy Rating, Raises Target Price to $20 - Moomoo
DTIL Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlitetm in Landmark CREDENCE Trial - Lelezard
[Form 4] PRECISION BIOSCIENCES INC Insider Trading Activity - Stock Titan
Director at Precision Bio (NASDAQ: DTIL) receives 20,979 restricted stock units - Stock Titan
Precision Biosciences (DTIL) director receives grant of 20,979 restricted stock units - Stock Titan
Precision BioSciences (DTIL) director receives grant of 20,979 RSUs - Stock Titan
Precision BioSciences stock (US74019P1084): shares edge higher amid biotech volatility - AD HOC NEWS
Executive at Precision BioSciences (DTIL) receives 57,389 RSU compensation award - Stock Titan
Precision BioSciences (DTIL) awards 107,604 RSUs to General Counsel - Stock Titan
Precision BioSciences (NASDAQ: DTIL) CEO receives 573,888 restricted stock units - Stock Titan
Tyra Biosciences Expands Precision Oncology Clinical Pipeline - asatunews.co.id
Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL) - The Globe and Mail
DTIL Stock Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Guggenheim Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $19 - Moomoo
DTIL Stock Price, Quote & Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Precision BioSciences Shareholders Approve Incentive Plan and Directors - The Globe and Mail
DTIL Reiterates by HC Wainwright & Co. -- Price Target Maintained at $60 - GuruFocus
Precision BioSciences (DTIL) Unveils Groundbreaking Data on PBGE - GuruFocus
Precision BioSciences Put Its ARCUS Gene Editing Data Front And Center - Finimize
Precision BioSciences, Inc. (DTIL) Discusses Updates on PBG and HBV Program and ELIMINATE-B Trial ResultsSlideshow (NASDAQ:DTIL) 2026-05-27 - Seeking Alpha
Precision BioSciences stock jumps on hepatitis B trial data By Investing.com - Investing.com South Africa
Precision BioSciences stock jumps on hepatitis B trial data - Investing.com
Precision BioSciences Reports Promising New Hepatitis B Trial Data - TipRanks
Why Is Precision BioSciences Stock Gaining Wednesday?Precision BioSciences (NASDAQ:DTIL) - Benzinga
Precision BioSciences Approves Amendments to 2019 Incentive Award Plan and Certificate of Incorporation - minichart.com.sg
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 - BioSpace
New PBGENE-HBV hepatitis B data from Precision BioSciences (Nasdaq: DTIL) - Stock Titan
Experimental gene edit targets hepatitis B DNA in early patient biopsies - Stock Titan
Precision BioSciences (DTIL) shareholders approve 3.8M-share incentive plan increase and officer exculpation - Stock Titan
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Precision Biosciences (DTIL) director gains 21,000 shares as RSUs vest into common stock - Stock Titan
Director at Precision BioSciences (DTIL) sees 21,000 RSUs vest into common stock - Stock Titan
Director Melinda Brown receives 21,000 DTIL shares as RSUs vest (DTIL) - Stock Titan
Precision BioSciences (DTIL) director gains 21,000 shares from RSU vesting - Stock Titan
Precision Biosciences (NASDAQ: DTIL) director’s 21,000 RSUs vest into shares - Stock Titan
H.C. Wainwright Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $60 - Moomoo
DTIL: Shareholders approved all proposals as the company advanced key clinical programs and strengthened its finances - TradingView
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINA - pharmiweb.com
Precision BioSciences Inc Annual Shareholders Meeting Transcript - GuruFocus
Precision Biosciences Inc (DTIL) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):